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Abstract
Backgrounds In coeliac disease, the prevalence of liver test
abnormalities (LTAs) is higher in patients with more severe
mucosal inflammation. In Crohn’s disease, prognosis is relat-
ed to the severity of mucosal inflammation.
Aim The aim of this study was to investigate whether the
presence of LTA predicts the occurrence of complicated dis-
ease behaviour in newly diagnosed Crohn’s disease.
Methods A retrospective cohort study was performed in
patients newly diagnosed with Crohn’s disease between
2002 and 2011. The complicated disease was defined as
the occurrence of stricturing and/or perforating disease.
LTAs were defined as a value of any of alkaline phospha-
tase (AP), gamma-glutamyl transpeptidase (GGT), aspar-
tate aminotransferase (AST), or alanine aminotransferase
(ALT) over the upper limit of normal.
Results Three hundred eighty-three patients were included, of
whom 34.1% had LTA. LTAs were mostly mild (less than two
times the upper limit of normal). During the 5-year follow-up,
33.1% of patients in the group with LTA developed
complicated disease behaviour compared to 14.6% in patients
without LTA (p < 0.001). The presence of LTAwas identified
as a risk factor for complicated disease behaviour (HR 2.6,
95% confidence interval (CI) 1.5–4.2, p < 0.0001).
Conclusions In newly diagnosed Crohn’s disease, the pres-
ence of LTA was an independent risk factor for the develop-
ment of complicated disease behaviour.
Keywords Inflammatory bowel disease . Prognosis .
Complications
Introduction
Liver test abnormalities (LTAs) are frequently observed in pa-
tients with inflammatory bowel disease (IBD), affecting be-
tween 3 and 50% of patients [1, 2]. In IBD patients, LTAs are
most frequently ascribed to the use of medication or the pres-
ence of hepatic steatosis [3]. For instance, Gisbert et al. follow-
ed 786 IBD patients for 5 years and found LTA in 15% of
patients, of which 43% were ascribed to thiopurines and hepat-
ic steatosis was considered the cause in 41% of patients [3].
Whether liver test abnormalities have any clinical signifi-
cance has recently been studied. Morsy and Hasanain found a
relation between clinical and endoscopic indices of severity
and levels of alkaline phosphatase (AP), alanine aminotrans-
ferase (ALT), and aspartate aminotransferase (AST) [15].
Mendes et al. demonstrated that inflammatory bowel disease
patients with any LTA had a worse survival compared to pa-
tients without LTA [2]. A similar relation has been observed in
the general population [4]. However, whether the presence of
LTA has any prognostic value with regard to disease behav-
iour in patients with Crohn’s disease (CD) has not been stud-
ied. Recently, a study in patients with newly diagnosed coeliac
disease demonstrated a relationship between the severity of
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mucosal inflammation and the presence of liver test abnormal-
ities (AST, ALT, and gamma-glutamyl transpeptidase (GGT))
[5]. Although the pathogenesis of inflammation in coeliac
disease has a different pathogenesis form of the inflammation
observed in CD, there are also similarities, such as an in-
creased bowel permeability. In CD, prognosis is related to
the severity of mucosa inflammation [6]. Therefore, we hy-
pothesized that in newly diagnosed CD, the presence of LTA
has a prognostic value with regard to the development of
complicated disease behaviour. We therefore retrospectively
studied the relationship of LTA with complicated disease be-
haviour in a cohort of all CD patients newly diagnosed be-




A retrospective study was performed in CD patients new-
ly diagnosed between 1 January 2002 and 31 December
2011 at the Leiden University Medical Centre (Leiden), a
tertiary IBD referral centre, and the Haga Hospital (The
Hague) and the Haaglanden Medical Centre (The Hague),
two large teaching hospitals. Patient charts were obtained
from an electronic patient database, using (CD) diagnosis
code B601^.
In order to be included, patients had to be newly
diagnosed with CD between 1 January 2002 and 31
December 2011, the diagnoses must have been made
in one of the three hospitals, and laboratory evaluation
including ALT, AST, AP, GGT, and C-reactive protein
(CRP) had to be available for analysis.
Patient characteristics such as demographics (age,
gender, weight, height), medical history, medication, in-
toxications, and medical examinations (laboratory evalu-
ation, ultrasound, viral evaluation, auto-immune evalua-
tion) were retrieved from the medical charts. Data on
the disease course were collected from medical charts.
These included the use of steroids, 5-ASA, immunosup-
pressive treatment, anti-TNF, hospitalization, complica-
tions, surgery, liver and biliary diseases, and mortality
during the disease course of CD. CD was classified
using the Montreal classification [7].
Timing of lab tests
Although in most cases multiple laboratory test results were
available, only the results of the first visit to the outpatient
clinic or emergency department were used. As these lab tests
were taken prior to the IBD diagnosis, or coincided with the
moment of diagnosis, these results were all obtained prior to
the initiation of any IBD therapy.
Definitions
The diagnosis of Crohn’s disease was made on the basis
of standard clinical, endoscopic, radiological, and path-
ological criteria [8]. The relevant liver tests were AP,
GGT, AST, and ALT. Liver test abnormalities were de-
fined as an elevation of any of these liver tests above
the upper limit of normal. During the study period, dif-
ferent upper limits of normal were used for the different
liver tests at different moments in the participating hos-
pitals. We therefore expressed all liver test values in this
paper as the quotient of the test result divided by the
upper limit of normal at that moment. An R value was
calculated to assess whether liver test abnormalities
were predominantly cholestatic, hepatocellular, or mixed
[9]. The R value was defined as the serum alanine
aminotransferase/upper limit of normal (ULN) divided
by the serum alkaline phosphatase/ULN. The value
R ≥ 5 is labelled as hepatocellular, R < 2 is labelled
as cholestatic, and 2 < R < 5 is labelled as Bmixed^.
Study outcome
The primary endpoint of this study was complicated disease
behaviour, defined as the occurrence of a stenosis, abscess,
fistula, or perforation, during the first 5 years of follow-up
after diagnosis. Other endpoints were hospitalizations and sur-
gery. In patients with complicated disease behaviour at diag-
nosis (B2 and/or B3, according to theMontreal classification),
follow-up ended at the next occurrence of a complication.
Hospitalization was defined as admission to the hospital spe-
cifically due to an exacerbation and/or complaints of CD.
Surgery was defined as the need for surgical intervention
due to complications or severe complaints of CD.
Statistical methods
Data were analysed using SPSS 20.0. To compare base-
line patient characteristics of the groups with and with-
out LTA at diagnosis, a chi-square test was used for
categorical variables, whereas an independent samples t
test was used for continuous variables. If the p value
was ≤0.05, the results were considered statistically
significant.
Survival analysis was performed using the Kaplan-Meier
analysis with log-rank test comparing patients with and with-
out liver test abnormalities. Other variables associated with a
complicated disease course were found using univariate Cox
regression analysis. Variables with p value ≤0.1 in univariate
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analysis were used for multivariate Cox regression analysis, in
which hazard ratios (HRs) were calculated.
Results
Study population
A total of 383 patients were included in the study
(Table 1). Of these patients, 62% were female. One pa-
tient with chronic liver disease (small duct Primary
Sclerosing Cholangitis (PSC)) was excluded. Of the 383
patients included in this study, 131 had LTA (34.1%).
Patients with LTA were older than those without LTA
and had a higher CRP. Groups were similar with regard
to the Montreal classification.
When patients were divided into three groups based on
their CRP, the prevalence of LTA was highest (48.6%) in
the group with the highest CRP (>58 mg/L) compared to
39.6% in the 16–58 mg/L group and 22.4% in the
<16 mg/L group (p < 0.0001). Patients with an elevated
level of AP or GGT most often had a CRP >16 mg/L (for
AP, 54/66 (p = 0.012); for GGT, 62/74 (p = 0.001)).
In general, LTAs were mild (Suppl. Table 4), and in
54% of patients with LTA, only a single liver test was
elevated (Suppl. Table 5). GGT was elevated most often
(Suppl. Table 6). The R ratio was calculated for all pa-
tients with LTA: in 79 patients (60%), the R ratio was <2
(cholestatic); in 39 patients (29.8%), the R ratio was be-
tween 2 and 5 (mixed); and in 3 patients (2.3%), the R
ratio was >5 (hepatocellular).
Thirty-two percent of patients had any comorbid dis-
ease, and 6% had an additional auto-immune disorder;
these proportions did not differ between patients with
and without LTA. No difference was observed with regard
to the presence of overweight, diabetes, or other features
of the metabolic syndrome. There was also no relationship
between the R ratio and the presence of overweight, dia-
betes, or other features of the metabolic syndrome.
Sixty-four percent of patients underwent abdominal ul-
trasound (Suppl. Table 4; 64.8% in the LTA group vs.
64.7% in the group without LTA), and the prevalence of
steatosis was similar between groups. Similarly, no signif-
icant differences were found between the prevalence of
biliary stones, sludge, hepatomegaly, or gallbladder
polyps or adenomyomatosis. Given the mild LTA, a full
analysis was not performed in all cases, but in the patients
with evaluation for viral or auto-immune liver disease,
this evaluation was negative (Suppl. Table 4).
Interestingly, 28 out of the 39 patients with perianal
disease at diagnosis were started on anti-TNF compared
to 165 out of the 344 patients without perianal disease (72
vs. 48%, p = 0.005).
Relation between the presence of LTA at diagnosis
and the disease course of Crohn’s disease
In total, 27% of patients developed complicated disease be-
haviour during 5 years of follow-up. Twenty-three percent had
surgery for CD, and 42% of patients were hospitalized during
the first 5 years of follow-up after diagnosis.
In patients with LTA, 33.6% developed complicated dis-
ease behaviour, compared to 14.7% of the patients without
LTA (p < 0.001; Table 1). Similarly, patients with LTA were
significantly more often hospitalized. Although the number of
patients undergoing surgery did not differ between groups, the
type of surgery did differ between groups: more often, a small
bowel resection was performed in LTA patients.
Suppl. Table 4 shows the relationship between each liver
test and the risk factor for developing complicated disease
behaviour, hospitalization, and surgery. Whereas GGT was
elevated most often, an elevated level of AP was associated
with an increased risk of complicated disease or hospitaliza-
tion. In Suppl. Table 5, we show that the risk for patients with
two abnormal liver tests of developing complicated disease
behaviour was higher than that for patients with one abnormal
test. However, the presence of more than two abnormal tests
did not further increase the risk.
As shown in Fig. 1a, both complication-free survival and
hospitalization-free survival were significantly longer in pa-
tients without LTA compared to patients with LTA (log rank:
p < 0.0001; log rank: p = 0.005, respectively; Fig. 1b). When
all patients were included, the difference for surgery-free sur-
vival was not significant (log rank: p = 0.057, Fig. 1c), but
when only patients with B1 behaviour at diagnosis were
analysed, patients with LTA had a shorter surgery-free surviv-
al (log rank: p = 0.017; Fig. 2).
As CRP was higher in LTA patients, we evaluated the inter-
play between the elevated CRP and the presence of LTA
(Fig. 3a–c). In patients with CRP <16 and 16–58 mg/L, the
presence of LTA was associated with a higher prevalence of
complicated disease behaviour compared to those without LTA
(CRP < 16 mg/L, log rank: p < 0.0001; CRP 16–58 mg/L, log
rank: p = 0.019; CRP > 58 mg/L, log rank: p = 0.101).
Univariate and multivariate analyses
To assess whether LTA is an independent risk factor for devel-
oping complicated disease behaviour, we performed univariate
(Table 2) and multivariate analyses. The univariate analysis
identified the presence of LTA, location of disease, and CRP
as risk factors for developing complicated disease behaviour.
The multivariate analysis showed that the presence of LTA
was associated with a higher risk of developing complicated
disease behaviour, as were ileal location and isolated upper
disease, whereas CRP at diagnosis was not (Table 3).
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Table 1 Patient characteristics
All patients (n = 383) LTA (n = 131) No LTA (n = 252)
Female, n (%) 240 (62.7) 85 (62) 155 (65)
BMI in kg/m2 (n = 202), n (%)
<18.5 44 (11.5) 16 (24.6) 28(20.4)
18.5–26 107 (27.9) 34 (54.7) 73 (49.2)
>26 51 (13.3) 16 (24.8) 35 (26.2)
Mean BMI in kg/cm2 (SD; IQR) 23.3 (5.9; 19.5–26.0) 23.3 (6.0; 19.0–26.1) 23.4 (5.8; 19.5–25.9)
Features of metabolic syndromea, n (%) 54 (14.1) 22 (16.8) 32 (12.7)
Use of non-IBD co-medication, n (%) 227 (59.3) 81 (59.6) 146 (59.1)
No comorbidity, n (%) 261 (68.1) 91 (66.9) 170 (68.8)
Other auto-immune disease, n (%) 23 (6) 9 (5.6) 14 (6.9)
Mean CRP at diagnosis in mg/L (SD; IQR) 56 (68; 10–78.5) 73.6 (77.6; 18–115.5)* 46.7 (61.1; 8–56)*
CRP in mg/L, n (%) ** **
<16 24 (20.5) 83 (41.0)
16–58 42 (39.6) 64 (31.5)
>58 51(47.7) 56 (27.6)
Age at diagnosis, n (%)
A1 33 (8.6) 10 (7.6) 23 (9.1)
A2 222 (58) 68 (30.6) 154 (61.1)
A3 128 (33.4) 53 (40.5) 75 (29.8)
Mean age at diagnosis in years (SD; IQR) 34.2 (16.8; 21–45) 36.7 (17.4; 23–49)* 32.9 (16.5; 20.3–43)*
Location at diagnosis, n (%)
Colonic 97 (25.3) 32 (24.4) 65 (25.8)
Ileal only 129 (33.7) 41 (31.3) 88 (31.8)
Ileocolonic 153 (39.9) 55 (35.9) 98 (38.9)
Upper GI disease 4 (1) 3 (2.3) 1 (0.4)
Behavior at diagnosis, n (%)
B1 281 (73.4) 93 (71.0) 188 (74.6)
B2 77 (20.1) 26 (19.8) 51 (20.2)
B3 25 (6.5) 12 (9.2) 13 (5.3)
Perianal involvement at diagnosis, n (%) 39 (10.2) 13 (9.9) 26 (10.3)
Smoking, n (%) 137 (35.8) 47(34.1) 90 (47)
Alcohol, n (%)
No alcohol 162 (61.4) 51 (59.3) 111 (62.4)
Use 95 (36) 30 (34.9) 65 (36.5)
Abuse 7 (2.7) 5 (5.8) 2 (1.1)
Liver test abnormalities at diagnosis, n (%) 131 (34.2)
Complication during follow-up, n (%) 81 (21.1) 44 (33.6)** 37 (14.7)**
Type of complication, n (%)
Stenosis 56 (18) 32(24.4)** 24 (9.5)**
Abscess 38 (9.9) 13 (9.9) 14 (5.5)
Fistula 36 (9.4) 11 (8.4) 15 (5.9)
Perforation 6 (1.6) 4 (3.1) 2 (0.8)
Hospitalization, n (%) 161 (42) 69 (52.7)* 92 (36.5)*
Surgery, n (%) 89 (23.2) 37(28.2) 52 (20.6)
Type of surgery, n (%) * *
Ileocecal resection 63 (16.4) 23 (17.7) 40 (15.9)
Colectomy 13 (3.4) 5 (3.81) 8 (3.1)
Small bowel resection 7 (1.8) 6 (4.5) 1 (0.4)
Other 6 (1.6%) 3 (2.3%) 3 (1.1%)
Medication used during follow-up, n (%)
Prednisone 244 (63.7) 85 (64.9) 159 (63.1)
Mesalamine 174 (45.5) 60 (45.8) 114 (45.2)
Immunomodulator 338 (88.3) 118 (90.1) 220 (87.3)
Anti-TNF 193 (50.4) 71 (54.2) 122 (48.4)
A chi-square test was used for categorical variables, and an independent samples t test was used for continuous variables. A1 = age at diagnosis
<16 years; A2 = age at diagnosis between 17 and 40 years; A3 = age at diagnosis >40 years; B1 = non-stricturing, non-penetrating disease; B2 =
stricturing disease; B3 = penetrating disease
LTA liver test abnormalities, SD standard deviation, IQR interquartile range, BMI body mass index, CRP C-reactive protein
*p < 0.05, for LTA vs. no LTA; **p < 0.001, for LTA vs. no LTA
a Features of metabolic syndrome: diabetes, hypercholesterolemia, and hypertension
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Fig. 2 Need for surgery, based on the presence of complicated disease
behaviour at diagnosis. a Patients without complicated disease at
diagnosis; p = 0.017 between patients with and without LTA (log rank).
b Patients with complicated disease at diagnosis; p = 0.56 between
patients with and without LTA (log rank)
Fig. 1 Occurrence of complications, hospitalization, and surgery, when
compared between patients with and without liver test abnormalities. a
Complication-free survival; p < 0.0001 between patients with andwithout
LTA (log rank). b Hospitalization-free survival; p = 0.005 between pa-
tients with and without LTA (log rank). c Surgery-free survival; p = 0.057
between patients with and without LTA (log rank). LTA liver test
abnormalities
R
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Using the multivariate analysis, the presence of LTA
(HR 1.8, p = 0.008, 95% CI 1.2–2.7) and the presence
of B2 behaviour (HR 1.9, p = 0.028, 95% CI 1.1–3.1)
were found to increase the risk of hospitalizations.
Patient age at diagnosis >17 years reduced the risk of
hospitalization (A2: p = 0.033, HR 0.32, 95% CI 0.24–
0.94; A3: p = 0.005, HR 0.32, 95% CI 0.14–0.70). B3
behaviour (p = 0.09), sex (p = 0.16), and BMI (p = 0.52)
did not influence the risk of hospitalization.
For surgery, when all patients were analysed, the presence
of complicated disease behaviour at diagnosis (B2: HR 3.6,
95% CI 2.3–5.8, p < 0.0001; B3: HR 5.5, 95% CI 2.0–10.7,
p < 0.0001) was identified as a risk factor.
However, when patients with complicated disease behav-
iour at diagnosis were excluded, the presence of LTA
(p = 0.015, HR 2.3, 95% CI 1.17–4.32) and either ileal
(p = 0.019, HR 2.99, 95% CI 1.2–7.45) or upper GI location
(p = 0.037, HR 9.57, 95% CI 1.148–79.3) were associated
with a higher risk of surgery.
Sensitivity analysis
A number of sensitivity analyses were performed: when
only patients with a normal CRP (below 5 mg/L; n = 27)
were included, the result of the Kaplan-Meier (KM) anal-
ysis for the presence of LTA was similar to that of the
analysis with all patients included. When only patients
with B1 behaviour were included (inflammatory disease
only; n = 281), the results of the KM LR and Cox regres-
sion analyses were similar to those of the entire cohort.
When only patients from the HAGA hospital were
analysed (n = 225), the results for the KM analysis and
Cox regression analysis were similar to those of the entire
cohort. When CRP was added to the Cox multivariate
model divided into three equal groups instead of as a
continuous variable, this did not alter the results (LTA:
p < 0.0001, HR 2.4; locations L1 and L4: p = 0.022,
HR 2.42, and p = 0.032, HR 5.5, respectively).
Discussion
In this study of 383 newly diagnosed Crohn’s disease patients,
patients with liver test abnormalities more often developed
complicated disease behaviour and more often were in need
of hospitalization or surgery within 5 years of diagnosis than
patients without LTA.
Fig. 3 Development of complicated disease, when compared between
patients with and without liver test abnormalities. a Patients with CRP
<16 mg/L; p < 0.0001 between patients with and without LTA (log rank).
b Patients with CRP 16–58 mg/L; p = 0.019 between patients with and
without LTA (log rank). c Patients with CRP >58 mg/L; p = 0.101
between patients with and without LTA (log rank)
R
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LTAs were present in 34.1% of patients. Most LTAs
were mild (less than two times the ULN), and in most
instances, only one liver test was elevated. The prevalence
of 34% corresponds to the 29% found by Mendes et al.
[2] with the prevalence in the literature varying between 3
and 50% [10]. As liver test abnormalities are often as-
cribed to medication (such as thiopurines) [3], we only
included patients with IBD prior to the initiation of
medication. The prevalence of chronic liver disease was
low: only one patient was excluded due to small duct
PSC, and the prevalence of steatosis diagnosed by ultra-
sound was 6%, similar to a recent paper demonstrating a
prevalence of 8.2% in IBD patients [11].
In coeliac disease, a relationship was found between
the presence of liver test abnormalities and disease activ-
ity. For instance, Zanini et al. found a correlation between
the degree of mucosal inflammation, graded according to
the Marsh-Oberhuber classification, and elevation of AST,
ALT, and GGT, whereas AP was not reported in [5]. In
our study of patients with active disease, the prevalence of
LTA was highest in patients with the highest CRP (48%
when CRP >58 mg/L) and this is in line with what is
observed in patients with coeliac disease.
In Crohn’s disease, the relationship between inflamma-
t ion and development of compl icat ions is wel l
established. For instance, Allez et al. demonstrated that
patients with more severe inflammation had a higher risk
of fistulising disease [6]. In our study, 27% of CD patients
developed a new episode of complicated disease behav-
iour within the first 5 years after diagnosis: 33% in
Table 2 Univariate analysis for
the LTA and development of
complicated disease behaviour
and hospitalizations
Complicated disease behaviour Hospitalization
HR 95% CI p value HR 95% CI p value
LTA 2.45 1.6–3.8 <0.0001 1.6 1.1–2.1 0.007
Age at diagnosis 0.92
A1 Ref
A2 0.55 0.34–0.89 0.015
A3 0.57 0.34–0.95 0.030
BMI 0.95
<18 Ref
18–26 0.67 0.42–1.1 0.102
>26 0.47 0.26–0.86 0.014
Location 0.43
Colonic Ref
Ileal only 1.9 1.005–3.7 0.048
Ileocolonic 1.7 0.91–3.2 0.096
Upper GI 5.1 1.2–5.1 0.031
Behavior 0.19
B1 Ref
B2 1.6 1.2–2.4 0.006
B3 1.7 0.97–2.9 0.07
Perianal disease 0.39 0.9
Smoking 0.53 0.9
CRP at diagnosis 1.003 1.001–1.006 0.010 0.238
Sex 0.71 1.3 0.9–1.8 0.095
A1 = age at diagnosis <17 years; A2 = age at diagnosis between 17 and 40 years; A3 = age at diagnosis >40 years;
B1 = non-stricturing, non-penetrating disease; B2 = stricturing disease; B3 = penetrating disease
Ref reference, LTA liver test abnormalities, CRP C-reactive protein
Table 3 Multivariate analysis for the LTA and development of
complicated disease behaviour
HR 95% CI p value
LTA 2.6 1.5–4.2 <0.0001
Location
Colonic Ref
Ileal only 2.4 1.1–5.1 0.022
Ileocolonic 1.9 0.95–3.9 0.69
Upper GI 6.6 1.2–26.2 0.032
CRP at diagnosis 1.004 1.001–1.007 0.19
LTA liver test abnormalities, CRP C-reactive protein, Ref reference
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patients with LTA and 14.6% in patients without LTA
(p < 0.0001). Using the KM log-rank survival analysis,
we showed that the presence of LTA was associated with
an increased prevalence of complicated disease behaviour,
as well as with increased need for hospitalizations.
As the mean CRP was higher in patients with LTA, we
analysed whether the increased prevalence of complica-
tions in LTA patients was only reflective of the higher
CRP concentration in this group. However, as shown in
Fig. 3a, patients with a CRP <16 mg/L but with LTA had
a higher risk of developing complicated disease compared
to those without LTA. This demonstrates that the presence
of LTA does not merely reflect a higher CRP concentra-
tion but may be a more sensitive indicator of an increased
risk of complicated disease behaviour than CRP.
Additional evidence for the independent role of LTA as
a risk factor for complicated disease behaviour comes
from the multivariate analysis. In the Cox regression anal-
ysis, the presence of LTA, as well as isolated ileal disease,
and the presence of upper GI disease are independent risk
factors for complicated disease behaviour. Additionally,
the presence of LTA was independently associated with
an increased risk of hospitalizations (HR 1.7, p = 0.023)
as well as surgery (HR 2.3, p = 0.015). For both these
outcomes, a relationship with degree of inflammation has
been suggested [12, 13].
Although the relationship between inflammation and
liver test abnormalities has previously been found in ul-
cerative colitis [1, 14, 15], this has, to our knowledge, not
been demonstrated previously in CD patients. In UC pa-
tients, Riegler et al. found a higher prevalence of LTA
predominantly in those patients with a higher level of
symptoms [14] and Morsy and Hasanain found a relation
between a higher endoscopic index of severity and an
elevated level of AP, ALT, and AST [15]. In these papers,
no follow-up data was available and the mechanism be-
hind this relationship was not explored in these papers.
Why the presence of LTA is associated with complicat-
ed disease behaviour is uncertain. But, as gut-liver
crosstalk has received much attention recently [16], a
number of theories have been suggested: increased intes-
tinal permeability in active CD may lead to exposure of
the liver to toxins or antigens of intestinal origin [5]. In
coeliac disease, a correlation has been observed between
transaminase level and the intestinal permeability index
[17]. Coeliac disease patients with more severe inflamma-
tion have a higher intestinal permeability, and this is
reflected in the higher prevalence of LTA. This may also
be the case in CD patients as increased permeability is a
hallmark of inflammation in CD and is associated with a
more severe disease course [5].
Secondly, enterohepatic circulation of lymphocytes
may play a role, in which memory cells from the gut
mucosa are recruited to the liver in response to aberrantly
expressed gut-homing molecules [18]. When these lym-
phocytes encounter an intestinal antigen in the liver, im-
mune activation occurs leading to inflammation [18]. The
combination of increased permeability and the presence of
gut-derived lymphocytes may cause liver test abnormali-
ties in patients with active Crohn’s disease.
We rejected hesitation to use immunomodulatory or bio-
logicals in LTA patients as a potential explanation, as these
medications may also induce liver test abnormalities, given
the fact that the use of these drugs was similar in LTA and
non-LTA patients.
The presence of perianal disease at diagnosis was not
related to complicated disease behaviour, in contrast to a
number of studies [19, 20]. However, 72% of patients
with perianal disease at diagnosis were started on anti-
TNF compared to 48% patients without perianal disease
(p = 0.005). Recently, Magro et al. demonstrated that
early treatment with either a biological or an immuno-
modulator can prevent progression to complicated disease
behaviour [21]. The high frequency of anti-TNF usage in
patients with perianal disease may have prevented pro-
gression to complicated luminal disease. Upper or isolat-
ed ileal location of disease was associated with a higher
risk of surgery, as demonstrated previously [22, 23].
When all patients were analysed, the patient with compli-
cated disease at diagnosis were also at an increased risk
of surgery (stricturing disease: HR 3.6; penetrating: HR
5.5), confirming earlier reports [22, 23]. The presence of
LTA was associated with an increased risk of surgery only
in those patients without complicated disease behaviour
at diagnosis.
In addition to their clinical relevance, our findings ap-
pear to underline the importance of the gut-liver axis and
emphasize the need for a better understanding of its mo-
lecular and genetic components. The limitations of our
study are its retrospective nature and the risk of referral
bias. We sought to minimize the latter by including only
newly diagnosed CD patients and patients from both a
tertiary and two large teaching hospitals. The retrospec-
tive nature means that the work-up of patients with LTA
was different in each case. However, in patients with
persistent LTA or in those with higher elevations of liver
tests, a more thorough evaluation was always performed,
minimizing the chance of missed chronic liver disease in
those patients.
In conclusion, the presence of LTA was an indepen-
dent risk factor for developing complicated disease,
need for hospitalization, and need for surgery in this
retrospective cohort study. Liver tests may be a widely
available, low-cost instrument that helps in identifying
high-risk patients who could benefit from a top-down
therapeutic regimen.
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